Abcam & Cancer Research UK join forces to accelerate cancer research

By Akshay Kedari  Date: 2020-07-09

Abcam & Cancer Research UK join forces to accelerate cancer research

Cancer Research UK, one of the world's biggest independent funder of cancer research, has recently joined forces with Abcam plc, a leading developer of life science tools and reagents, to commercialize and develop novel custom antibodies to strengthen cancer research.

According to the terms of this partnership, Abcam would create custom protein-based reagents to targets that are recognized by researchers at Cancer Research UK. These antibodies would support the ongoing research and progress the understanding of cancer biology. Moreover, it would potentially be the basis for novel therapies as well as help generate new diagnostic tools.

Upon request, Abcam would deliver unique antibodies created during the terms of the agreement to researchers funded by Cancer Research UK for a pre-determined span of exclusivity in correspondence to that antibody. 

Meanwhile, Abcam’s co-location in key technology spots throughout the world and global supply capability would allow these innovative reagents to be easily available across wider diagnostic and research development community.

Speaking on the move, Tony Hickson, CBO, Cancer Research UK, said that the company is thrilled to collaborate with Abcam to develop tools that scientists require to help advance their understanding of cancer and to extend its access to biological reagents.

Additionally, Abcam’s “end-to-end” expertise and antibody development capabilities would support works of numerous researchers with antibody reagents that could be utilized from the initial stages of R&D right to the clinical trials.

As for Dr. John Baker, SVP of Product Portfolio Innovation, Abcam, the company is delighted to partner with Cancer Research UK to strengthen research by scientist and offer them easy access to validated and specific reagents, thereby helping them attain future breakthrough quickly.

Prior to this news, Abcam had made headlines when it announced that it has purchased assets of oncology product portfolio and gene editing platform from Applied StemCell, Inc. (ASC) for life science diagnostic and research markets. 
 

Source credit: https://www.abcam.com/index.html?pageconfig=news&rid=17091

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Tiger Global looking to raise USD 10 billion to create new venture fund

Tiger Global looking to raise USD 10 billion to create new venture fund

By Akshay Kedari

American investment firm Tiger Global is reportedly looking to create a capital fund for startups by securing USD 10 billion from investors. So far, the company has participated in over 100 investment rounds since the past three months and has manage...

Urban Company secures USD 190 million in funding round led by Prosus

Urban Company secures USD 190 million in funding round led by Prosus

By Akshay Kedari

Urban Company, an Indian gig marketplace that provides home maintenance services, has secured USD 190 million in a funding round which was led by Prosus N.V. Other participants in the fundraising included companies such as Steadview Capital, Tiger Gl...

Samsung might launch a foldable Android tablet in first quarter of 2022

Samsung might launch a foldable Android tablet in first quarter of 2022

By Akshay Kedari

After introducing three foldable smartphones in the past couple of years, South Korean multinational conglomerate Samsung Electronics is reportedly working on its first tri-folding Android tablet. According to reliable sources, the new product is lik...

Remote hiring startup Deel secures USD 156 million in Series C funding

Remote hiring startup Deel secures USD 156 million in Series C funding

By Akshay Kedari

Deel, a company that specializes in offering recruitment, payroll, and compliance tools, has reportedly secured USD 156 million during a Series C funding round which was led by YC Continuity Fund. The California-based startup has now reached a valuat...

Audi unveils the A6 e-Tron concept with 700 km range and 800 Nm torque

Audi unveils the A6 e-Tron concept with 700 km range and 800 Nm torque

By Akshay Kedari

Audi AG, a German multinational auto manufacturer of luxury vehicles has unveiled the A6 e-Tron concept which is soon likely to be made available globally. The production version which is expected to have a range of 700 km (more than 400 miles) is to...